Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $974.0 million.

  • Arcus Biosciences' Liabilities and Shareholders Equity fell 25.08% to $974.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year decrease of 11.03%. This contributed to the annual value of $1.1 billion for FY2024, which is 5.02% up from last year.
  • Latest data reveals that Arcus Biosciences reported Liabilities and Shareholders Equity of $974.0 million as of Q3 2025, which was down 9.40% from $1.1 billion recorded in Q2 2025.
  • Arcus Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $1.6 billion during Q4 2021, with a 5-year trough of $839.3 million in Q3 2021.
  • In the last 3 years, Arcus Biosciences' Liabilities and Shareholders Equity had a median value of $1.2 billion in 2023 and averaged $1.2 billion.
  • As far as peak fluctuations go, Arcus Biosciences' Liabilities and Shareholders Equity soared by 430.88% in 2021, and later dropped by 25.08% in 2025.
  • Arcus Biosciences' Liabilities and Shareholders Equity (Quarterly) stood at $1.6 billion in 2021, then dropped by 18.34% to $1.3 billion in 2022, then fell by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.1 billion in 2024, then decreased by 25.08% to $974.0 million in 2025.
  • Its last three reported values are $974.0 million in Q3 2025, $1.1 billion for Q2 2025, and $1.2 billion during Q1 2025.